Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT04282850
Other study ID # IRB00182159
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date July 10, 2023
Est. completion date January 2025

Study information

Verified date June 2023
Source Johns Hopkins University
Contact Eunice Yang, MD PhD
Phone 571-472-3270
Email Eunice.Yang@inova.org
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a prospective non-blinded randomized control pilot study comparing the effect of pulmonary vein isolation against medical management of atrial fibrillation in patients with Heart Failure with preserved Ejection Fraction (HFpEF).


Description:

Recent studies using PVI for rhythm control in patients with heart failure with reduced ejection fraction (HFrEF) have shown improvement in systolic ejection fraction, exercise capacity, quality of life, and a significant reduction in all-cause mortality. The PVI procedure has been shown to be safe and comparably effective in treating Atrial Fibrillation (AF) in HFpEF patients, but no studies have yet demonstrated the effects of catheter ablation on exercise capacity or clinical outcomes. The investigators propose a prospective, non-blinded randomized control pilot study to assess the feasibility of conducting larger scale studies to determine if there are differences between catheter ablation with medical management on exercise capacity and quality of life in HFpEF patients with AF. The investigators' study will be powered for AF burden reduction, and the investigators hope to use the effect size on exercise capacity and heart failure events to help determine power for larger clinical studies that will follow to shed light on how invasive management of atrial fibrillation may impact the natural history of individuals with these two cardiovascular conditions.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 60
Est. completion date January 2025
Est. primary completion date January 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years to 90 Years
Eligibility Inclusion Criteria: - between 18 to 90 years of age, male or female - Left Ventricular Ejection Fraction (LVEF) > 50% by echocardiogram during routine screening or within 12 months prior to enrollment day. - Symptoms of heart failure requiring treatment with diuretic therapy for at least 30 days preceding enrollment. - Symptomatic paroxysmal or persistent atrial fibrillation. - Paroxysmal atrial fibrillation defined as recurrent AF (at least 2 episodes) that terminated spontaneously within 7 days - Persistent AF was defined as AF which is sustained beyond 7 days, or lasting less than 7 days but necessitating pharmacologic or electrical cardioversion - Included within the category of persistent AF is "long-standing persistent AF" defined as continuous AF of greater than 1 year in duration - AF episodes had to be documented in the last 3 months prior to enrollment by ECG, Holter monitor, Loop recorder, memory of the implanted device, or any suitable device. - Current symptoms of heart failure (NYHA II-IV) at the enrollment visit (Visit 1) - Structural heart disease evidenced by one or both of the following echocardiographic findings (done during the transthoracic echocardiography (TTE) within 6 months of enrollment) - Left atrial enlargement (LAE) defined as LA width > 3.8 cm or LA length > 5.0 cm, or LA area > 20 cm2 or LA volume > 55 mL or LA volume index > 29 ml/m2. (of note, LA length greater than 6.0 cm will be excluded) - Left ventricular hypertrophy (LVH) defined by septal thickness or posterior wall thickness > 1.0 cm - And at least one of the following: - A heart failure hospitalization lasting over 12 hours and including intravenous diuretics at a healthcare facility within 12 months prior to the enrollment visit. - An elevated pro-brain natriuretic peptide (BNP) (>100 pg/mL, or N-terminal pro b-type natriuretic peptide (NT-proBNP)>300 pg/mL) - Hemodynamic testing consistent with HFpEF physiology including pulmonary capillary wedge pressure (PCWP) (or LVEDP) = 15 mmHg. Exclusion Criteria: - Previous left heart ablation procedure for AF - Contraindication to chronic anticoagulation therapy or heparin - Longstanding atrial fibrillation, defined here as greater than 3 years of persistent atrial fibrillation - Severe left atrial dilatation, with LA length > 6.0 cm, optimally from parasternal long view - Acute coronary syndrome within 4 weeks as defined by electrocardiographic (ECG) ST segment depression or prominent T-wave inversion and/or positive biomarkers of necrosis (e.g. troponin) in the absence of ST-segment elevation and in an appropriate clinical setting (chest discomfort or angina equivalent). - Cardiac surgery, angioplasty, or cerebrovascular accident within 4 weeks prior to enrollment. - Planned cardiovascular intervention - Listed for heart transplant - Cardiac assist device implanted or need for mechanical hemodynamic support or inpatient admission - Life expectancy less than 1 year - Uncontrolled hypertension, defined as resting systolic blood pressure >190 and/or resting diastolic pressure>110 - Chronic Kidney Disease (CKD) stage 4-5 (GFR<25 ml/min/1.73m2), or on hemodialysis - Cardiac diagnosis in addition to or other than HFpEF: - Active myocarditis - Hypertrophic obstructive cardiomyopathy - Severe valvular disease - Restrictive or constrictive cardiomyopathy, including known amyloidosis, sarcoidosis, hemochromatosis - Complex congenital heart disease - Constrictive pericarditis - Severe pulmonary hypertension (RVSP > 60 mmHg), not secondary to HFpEF - Non-cardiac pulmonary edema - Clinical evidence of digoxin toxicity - Sepsis - Inability to comply with planned study procedures - Pregnancy or nursing mothers - Uncontrolled hypothyroidism or hyperthyroidism - BMI of >65 kg/m2

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Pulmonary Vein Isolation
The intervention will involve standard of care electrophysiology ablation for rhythm management of atrial fibrillation with a procedure called a pulmonary vein isolation.

Locations

Country Name City State
United States Inova Heart and Vascular Institute Fairfax Virginia

Sponsors (3)

Lead Sponsor Collaborator
Johns Hopkins University Biosense Webster, Inc., Medtronic

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in AF burden as assessed by difference in percentage of time an individual is in AF AF burden, described as the percentage of time an individual is in AF relative to the total amount of time analyzed. This outcome will be assessed at multiple intervals following intervention arm, using a continuous, implantable heart rhythm monitor. The investigators' focus will be on the change between pre-intervention AF burden and AF burden at 6 month follow-up. 3, 6, 9, and 12 months from intervention
Secondary All-cause mortality All deaths within 12 months of the intervention arm. 12 months
Secondary Number of cardiovascular mortalities The number of deaths attributable to cardiovascular causes occurring within 12 months of the intervention arm 12 months
Secondary Number of all-cause hospitalizations The total number of inpatient hospitalizations within 12 months following the intervention. 12 months
Secondary Number of heart failure hospitalizations The total number of inpatient hospitalizations attributable to heart failure exacerbations within 12 months following the intervention. 12 months
Secondary Change in patient-reported quality of life as assessed by Kansas City Cardiomyopathy Questionnaire The Kansas City Cardiomyopathy Questionnaire is a 23-item, self-administered instrument that quantifies physical function, symptoms (frequency, severity and recent change), social function, self-efficacy and knowledge, and quality of life. A change of 10 points or more is considered not only clinically significant but also carries prognostic implications for event-free survival in heart failure patients. At enrollment (baseline) and 6 months following intervention
Secondary Change in NT pro-BNP levels Serum biomarker associated with congestive heart failure symptoms, measured in (mg/ml). At enrollment (baseline) and 6 months following intervention
Secondary Change in exercise capacity as assessed by the 6 minute walk distance test Pre-intervention arm and 6 month post-procedural exercise capacity will be assessed using change in 6 minute walk distance, defined as the total distance (in meters) traversed during 6 minutes of time. This is well-validated measure of functional capacity and prognostic marker in patients with heart failure. At baseline and 6 months post intervention
See also
  Status Clinical Trial Phase
Recruiting NCT05654272 - Development of CIRC Technologies
Completed NCT04571385 - A Study Evaluating the Efficacy and Safety of AP30663 for Cardioversion in Participants With Atrial Fibrillation (AF) Phase 2
Terminated NCT04115735 - His Bundle Recording From Subclavian Vein
Completed NCT05366803 - Women's Health Initiative Silent Atrial Fibrillation Recording Study N/A
Completed NCT02864758 - Benefit-Risk Of Arterial THrombotic prEvention With Rivaroxaban for Atrial Fibrillation in France
Recruiting NCT05442203 - Electrocardiogram-based Artificial Intelligence-assisted Detection of Heart Disease N/A
Completed NCT05599308 - Evaluation of Blood Pressure Monitor With AFib Screening Feature N/A
Completed NCT03790917 - Assessment of Adherence to New Oral anTicoagulants in Atrial Fibrillation patiEnts Within the Outpatient registrY
Enrolling by invitation NCT05890274 - Atrial Fibrillation (AF) and Electrocardiogram (EKG) Interpretation Project ECHO N/A
Recruiting NCT05316870 - Construction and Effect Evaluation of Anticoagulation Management Model in Atrial Fibrillation N/A
Recruiting NCT05266144 - Atrial Fibrillation Patients Treated With Catheter Ablation
Not yet recruiting NCT06023784 - The Impact of LBBAP vs RVP on the Incidence of New-onset Atrial Fibrillation in Patients With Atrioventricular Block N/A
Recruiting NCT05572814 - Transform: Teaching, Technology, and Teams N/A
Recruiting NCT04092985 - Smart Watch iECG for the Detection of Cardiac Arrhythmias
Completed NCT04087122 - Evaluate the Efficiency Impact of Conducting Active Temperature Management During Cardiac Cryoablation Procedures N/A
Completed NCT06283654 - Relieving the Emergency Department by Using a 1-lead ECG Device for Atrial Fibrillation Patients After Pulmonary Vein Isolation
Recruiting NCT05416086 - iCLAS™ Cryoablation System Post-Market Clinical Follow-up (PMCF) Study N/A
Completed NCT05067114 - Solutions for Atrial Fibrillation Edvocacy (SAFE)
Completed NCT04546763 - Study Watch AF Detection At Home
Completed NCT03761394 - Pulsewatch: Smartwatch Monitoring for Atrial Fibrillation After Stroke N/A